Business
Liquidia Corporation Reports First Quarter 2026 Financial Results
YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025Actively screening PH
About this update from Liquidia Corporation
[{"type":"image","alt":"Liquidia Technologies, Inc.","displaySize":"","headline":null,"caption":"Liquidia Technologies, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/27692c5b070211d5324fd115a83fc89f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D6Ygjok6K2bMzW1cPyAdIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNA--/https://media.zenfs.com/en/globenewswire.com/27692c5b070211d5324fd115a83fc89f","width":300,"height":96},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/D6Ygjok6K2bMzW1cPyAdIA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNA--/https://media.zenfs.com/en/globenewswire.com/27692c5b070211d5324fd115a83fc89f","width":300,"height":96}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026","length":132,"tagName":"p"}]},{"val":[{"type":"text","content":"Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025","length":228,"tagName":"p"}]},{"val":[{"type":"text","content":"Actively screening PH-ILD patients in Phase 4 Tyvaso® and Tyvaso DPI® transition study and pivotal Phase 3 Re-Spire study of L606","length":129,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":608,"olType":false},{"type":"text","content":"MORRISVILLE, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the first quarter ended March 31, 2026. The company will also host a webcast at 8:30 a.m. ET on May 11, 2026, to discuss its financial results and provide a corporate update.","length":453,"tagName":"p"},{"type":"text","content":"Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “In its third full quarter on the market, YUTREPIA continued to demonstrate susta...